Author details

Full Name

Cyril H Benes

Affiliation

ORCID

Career Start Year

1996

Papers

139

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36914816	SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.	Nat Cancer	2023
37407818	Therapy-induced APOBEC3A drives evolution of persistent cancer cells.	Nature	2023
37380628	A landscape of response to drug combinations in non-small cell lung cancer.	Nat Commun	2023
35197630	Effective drug combinations in breast, colon and pancreatic cancer cells.	Nature	2022
35905710	High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.	Cell Rep	2022
36347861	Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.	Nat Commun	2022
35420673	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.	Cancer Discov	2022
36712364	Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.	PNAS Nexus	2022
36506869	Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.	Cancer Res Commun	2022
36480603	IFITM proteins assist cellular uptake of diverse linked chemotypes.	Science	2022
34676056	Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.	Oncotarget	2021
33778784	Alginate-based 3D cancer cell culture for therapeutic response modeling.	STAR Protocols	2021
34088831	Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i>-amplified Neuroblastoma.	Mol Cancer Ther	2021
33762304	Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastoma.	Proc Natl Acad Sci U S A	2021
34343607	Screening and Validation of Molecular Targeted Radiosensitizers.	Int J Radiat Oncol Biol Phys	2021
34315769	Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.	Mol Cancer Ther	2021
34624218	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.	Cancer Cell	2021
31359406	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.	International Journal of Cancer	2020
31594766	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3KÎ± Inhibitors in Breast Cancer.	Cancer Discov	2020
31810998	Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction.	Clinical Chemistry	2020
32086345	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.	Clin Cancer Res	2020
32649904	Pharmacological Targeting of Vacuolar H-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer.	Cell Chemical Biology	2020
32620799	Predicting and affecting response to cancer therapy based on pathway-level biomarkers.	Nat Commun	2020
31097696	Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.	Nat Commun	2019
31645751	Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.	Nat Chem Biol	2019
30607635	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.	Breast Cancer Research and Treatment	2019
30224339	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.	Clin Cancer Res	2019
30348635	The Ewing Family of Tumors Relies on BCL-2 and BCL-X to Escape PARP Inhibitor Toxicity.	Clinical Cancer Research	2019
30327306	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.	Clinical Cancer Research	2019
31127149	Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.	Leukemia	2019
30858180	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.	Mol Syst Biol	2019
31155233	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.	Cell	2019
31109923	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.	Cancer Discov	2019
31249028	Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.	Science	2019
30777010	Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.	BMC Bioinformatics	2019
31324888	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.	Oncogene	2019
29769286	Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.	Sci Transl Med	2018
30460326	TP53 mutation status: emerging biomarker for precision radiation medicine?	Oncoscience (discontinued)	2018
30028875	Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin.	PLoS ONE	2018
30026325	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.	Cancer Research	2018
30553813	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.	iScience	2018
30157175	BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.	PLoS Biology	2018
30254093	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.	Cancer Discovery	2018
30254092	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer.	Cancer Discov	2018
30297875	MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.	Nat Chem Biol	2018
29959327	Harnessing synthetic lethality to predict the response to cancer treatment.	Nat Commun	2018
30135190	A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.	Cancer Research	2018
29358035	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.	Cancer Cell	2018
29229604	Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.	Cancer Res	2018
29444439	Differential Effector Engagement by Oncogenic KRAS.	Cell Rep	2018